Immunological effects of thalidomide and its chemical and functional analogs

Critical Reviews in Immunology

Volumn 22, Issue 5-6, 2002, Pages 425-437

  Dredge, Keith ^a   Marriott, J Blake ^a   Dalgleish, Angus G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Analogs; Costimulation; Cytokine; Immunomodulatory; Thalidomide; Tumor

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CDC 801; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 5; LENALIDOMIDE; PHOSPHODIESTERASE IV; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CANCER; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; ENTERITIS; GLIOBLASTOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFLAMMATORY DISEASE; KIDNEY CARCINOMA; LEPROSY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; T LYMPHOCYTE; TUBERCULOUS MENINGITIS;

ADJUVANTS, IMMUNOLOGIC; ANGIOGENESIS INHIBITORS; ANTIVIRAL AGENTS; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM; NEOPLASMS; THALIDOMIDE;

EID: 0037992779     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Fullerton PM, Kremer M. Neuropathy after intake of thalidomide. Br Med J 1961; 2:855-858.
2. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; 2:1358.
3. Sheskin J. Further observation with thalidomide in lepra reactions. Lepr Rev 1965; 36:183-187.
4. Iyer GCS, Languillon J, Ramanujam K, Tarabini-Castellani G, De las Aguas JT, Bechelli LM, Uemura K, Martinez DV, Sundaresan T. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 1971; 45:719-732.
5. Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168:408-414.
6. Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999; 583:538-540.
7. Raje N, Anderson K. Thalidomide-a revival story. N Engl J Med 1999; 341:1606-1609.
8. Hales B. Thalidomide on the comeback trail. Nat Med 1999; 5:489-490.
9. Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999; 21:319-330.
10. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Eng J Med 1999; 341:1565-1571.
11. Rajikumar SV. Thalidomide in the treatment of multiple myeloma. Expert Rev Anticancer Ther 2002; 1:20-28.
12. Richardson P, Hideshima T, Anderson K. Thalidomide in multiple myeloma. Biomed Pharmacother 2002; 56:115-128.
13. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2002; 82:812-817.
14. Fine HA, FiggWA, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Pluda JM, Yung WK. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18:708-715.
15. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000; 23:319-321.
16. Gutheil J, Finucane D. Thalidomide therapy in refractory solid tumor patients. Br J Haematol 2000; 110:754.
17. Teo SK, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI, Thomas SD. Thalidomide in the treatment of leprosy. Microbes Infect 2002; 4:1193-1202.
18. Cattelan AM, Trevenzoli M, Aversa SM. Recent advances in the treatment of AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2002; 3(7):451-462.
19. Ossandon A, Cassara EA, Priori R, Valesini G. Thalidomide: focus on its employment in rheumatologic diseases. Clin Exp Rheumatol 2002; 20(5):709-718.
20. Bohmeyer J, Achenbach A, Westenberger M, Stadler R. Thalidomide therapy of cutaneous lupus erythematosus. Hautarzt 2002; 53(11):744-748.
21. Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, Wettstein AR, Field A. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002; 17(2):135-139.
22. Fu LM, Fu-Liu CS. Thalidomide and tuberculosis. Int J Tuberc Lung Dis 2002; 6(7):569-572.
23. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Levin LS, Colvin OM, Wingard JR, Saral R, Griffin C, Shah N, Zehnbauer BA. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326:1055-1058.
24. Schuler U, Ehninger G. Thalidomide: rationale for renewed use in immunological disorders. Drug Safety 1995; 12:364-369.
25. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
26. Marriott JB, Westby M, Dalgleish AG. The therapeutic potential of TNF-α inhibitors old and new. Drug Discov Today 1997; 2:273-282.
27. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS. Inhibition of NF-κB activity by thalidomide through suppression of IκB activity. J Biol Chem 2001; 276(25):22382-22387.
28. Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336(15):1066-1071.
29. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281(5383):1680-1683.
30. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19(8):5785-5799.
31. Mayo MW, Baldwin AS. The transcriptional factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000; 1470(2): M55-62.
32. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91:4082-4085.
33. O'Byrne KJ, Dalgleish AG, Browning MJ, Stewart WP, Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000; 36:151-169.
34. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4:408-414.
35. McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lacmann PJ, Lockwood CM, Ewan PW. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99:160-167.
36. Moller DR, Wysocka M, Greenlee BM, MaX, Wahl L, Flockhart DA, Trinchineri G, Karp CL. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159:5157-5161.
37. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187:1885-1892.
38. 3]-thymidine-dependence on the primary stimulant. Int Immunopharmacol 2002; 2:1143-1153.
39. + cells. Clin Exp Immunol 2002; 130:75-84.
40. Verbon A, Juffermans NP, Speelman P, vanDeventer SJ, tenBerge IJ, Guchelaar HJ, van Der Poll T. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob Agents Chemother 2000; 44(9):2286-2290.
41. Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the intergroupe francophone du myelome (IFM). Hematol J 2002; 3(4):185-192.
42. Leleu X, Magro L, Fawaz A, Bauters F, Facon T, Yakoub-Agha I. Efficacy of a low dose of thalidomide in advanced multiple myeloma. Blood 2002; 100(4):1519-1520.
43. Wu KL, Schaafsma MR, Lokhorst HM, Wijermans PW, van der Holt B, Sonneveld P. Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%. Ned Tijdschr Geneeskd 2002; 146:1445-1448.
44. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002; 13(7):1116-1119.
45. Raijkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20(21):4319-4323.
46. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96:2943-2950.
47. Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, Opelz G, Goldschmidt H. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 2002; 100(6):2263-2265.
48. Neben K, Moehler T, Kraemer A, Benner A, Egerer G, Ho AD, Goldschmidt H. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 2001; 115:605-608.
49. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98:210-216.
50. Battistini L, Borsellino G, Sawicki G, Poccia F, Salvetti M, Ristori G, Brosnan CF. Phenotypic and cytokine analysis of human peripheral blood γδ T cells expressing NK cell receptors. J Immunol 1997; 159:3723-3730.
51. Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002; 20:302-306.
52. Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Lebourgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A. Phase II trial of thalidomide in renal cell carcinoma. Ann Oncol 2002; 13(7):1029-1035.
53. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ, Ruiz-Palacios GM. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996; 10:1501-1507.
54. Haslett PA, Klausner JD, Makonkawkeyoon S, Moreira A, Metatratip P, Boyle B, Kunachiwa W, Maneenkarn N, Vongchan P, Corral LG, Elbeik T, Shen Z, Kaplan G. Thalidomide stimulates T cell responses and interleukin-12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999; 15(13):1169-1179.
55. Hanekom WA, Hughes J, Haslett PA, Apolles P, Gansio V, Allin R, Goddard E, Hussey GD, Kaplan G. The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children. J Infect Dis 2001; 184(9):1192-1196.
56. Marriott JB, Cookson S, Carlin E, Youle M, Hawkins DA, Nelson M, Pearson M, Vaughan AN, Gazzard B, Dalgleish AG. A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Res Hum Retroviruses 1997; 13(18):1625-1631.
57. Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G, Stirling DI. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996; 39:3238-3240.
58. Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Stirling DI, Kaplan G. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996; 2:506-515.
59. Muller GW, Shire MG, Wong LM Corral LG, Patterson RT, Chen Y, Stirling DI. Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett 1998; 8:2669-2674.
60. Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT, Chen Y, Kaplan G, Stirling DI. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999; 9:1625-1630.
61. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNF-α. J Immunol 1999; 163:380-386.
62. Marriott JB, Clarke IA, Czajka A, Dredge K, Childs K, Man HW, Schafer P, Govinda S, Muller GW, Stirling D, Dalgleish AG. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase dependent apoptosis is associated with altered expression of bcl-2 family proteins. Cancer Res 2003; 63(3):593-599.
63. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol 1998; 25:964-969.
64. Prehn JL, Landers C, Muller GW, Man HW, Stirling DI, Targan SR. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogs. J Clin Immunol 2001; 21(5):357-364.
65. Tsenova L, Mangaliso B, Muller G, Chen Y, Freedman VH, Stirling D, Kaplan G. Use of IMiD3, a thalidomide analog, as an adjuvant to therapy for experimental tuberculous meningitis. Antimicrob Agents Chemother 2002; 46:1887-1895.
66. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352:1586-1589.
67. Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, Dalgleish AG. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002; 168:4914-4919.
68. Moreira AL, Corral LG, Ye WG, Johnson B, Stirling DI, Muller GW, Freedman VH, Kaplan G. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Human Retroviruses 1997; 13:857-863.
69. Marriott JB, Westby M, Cookson S, Guckian M, Goodbourn S, Muller G, Shire MG, Stirling D, Dalgleish AG. CC-3052: a water soluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production. J Immunol 1998; 161:4236-4243.
70. La Maestra L, Zaninoni A, Marriott JB, Lazzarin A, Dalgleish AG, Barcellini W. The thalidomide analogue CC-3052 inhibits HIV-1 and tumor necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro. Clin Exp Immunol 2000; 119:123-129.
71. Raje N, Anderson KC. Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 2002; 14:635-640.
72. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson K. Apoptotic signalling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99(12):4525-4230.
73. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15:1950-1961.
74. Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neuro-Oncol 1999; 43:109-114.
75. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG. Novel thalidomide analogs display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87(10):1166-1172.
76. Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, Anderson KC, D'Amato RJ. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 2002; 62:2300-2305.
77. Scheffler MR, Oliver SD, Allen E, Thomas SD. The safety, tolerability and pharmacokinetics of CDC-801, a novel TNF-alpha inhibitor, given as single oral doses, 50 mg to 1 gm. American Association of Pharmaceutical Scientists, New Orleans Meeting, November 1999.
78. Teo S, Oliver S, Harris J. Pharmacokinetics of the thalidomide analogue CC-1088 after multiple oral dose in healthy male subjects, American Association of Pharmaceutical Scientists, New Orleans Meeting, November 1999.
79. Richardson PG, Schlossman RL, Hideshima T, Davies F, LeBlanc R, Catley L, Doss D, Kelly KA, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo J, Chauhan D, Munshi N, Weller E, Thomas S, Zeldis J, Anderson KC. A Phase I study of oral CC-5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). Blood 2001; 98(Suppl. 1):775a.
80. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of Phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood 2001; 98(Suppl. 1):775a.
81. Schey SA, Jones RW, Raj K, Streetley M. A phase I study of an immunomodulatory drug (CC-4047), a structural analogue of thalidomide, in relapsed/refractory multiple myeloma. Proceedings of the 31st Annual Meeting of the International Society for Experimental Haematology, 2002.
82. Marriott JB, Clarke IA, Dredge K, Pandha H, Kristaleit H, Polychronis A, Muller GW, Stirling D, Dalgleish AG. Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation. Br J Cancer 2002; 86:S26.